Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Lazarus

Orthopaedic Surgery Bensalem, PA Medical Doctor

NPI 1497793657 CMS profile 889278

3300 Tillman Dr Fl 2, Bensalem, PA 19020

Open in the dashboard

General payments

$6,395,873

233 records reported · program years 2019–2025

Research payments

$5,053

Paid to them · 8 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$33,946 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Mark Lazarus of Bensalem, PA is reported in the CMS Open Payments database as having received $6,395,873 across 233 general payments and $5,053 in research payments paid to them. Separately, studies naming them as principal investigator received $33,946 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $744,065 18
2024 General $1,251,230 48
2023 General $1,149,156 31
2022 General $951,197 22
2022 Research $2,319 1
2021 General $833,022 42
2020 General $674,705 21
2019 General $792,498 51
2019 Research $2,734 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Lazarus
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Mark Lazarus were reported at $744,065. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Mark Lazarus Orthopaedic Surgery median Middle half National median
2019 $792,498 $644 $140–$2,844 $163
2020 $674,705 $312 $75–$1,860 $114
2021 $833,022 $520 $117–$2,495 $132
2022 $951,197 $598 $128–$2,731 $149
2023 $1,149,156 $461 $128–$2,264 $160
2024 $1,251,230 $497 $134–$2,475 $164
2025 $744,065 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $4,928,562 157 payments
  2. Wright Medical Technology, Inc. $1,466,931 67 payments
  3. Acumed LLC $96 2 payments
  4. Arthrosurface Incorporated $77 1 payment
  5. FX Shoulder USA, Inc $56 1 payment
  6. Carbofix Orthopedics Inc $51 1 payment
  7. DePuy Synthes Sales Inc. $33 1 payment
  8. Catalyst OrthoScience $33 1 payment
  9. Paladin Technology Solutions $20 1 payment
  10. Ferring Pharmaceuticals Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $6,219,352 56 payments
  2. Consulting Fee $136,460 57 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,000 23 payments
  4. Travel and Lodging $10,949 29 payments
  5. Food and Beverage $5,112 68 payments
Products named General payments · program years 2019–2025
  1. AEQUALIS PERFORM $4,881,839 68 payments
  2. AEQUALIS $1,421,899 17 payments
  3. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $92,560 70 payments
  4. TORNIER PERFORM REVERSED AUGMENTED GLENOID $28,216 8 payments
  5. TORNIER PERFORM ANATOMIC AUGMENTED GLENOID $28,044 6 payments
  6. TORNIER PERFORM REVERSED GLENOID $28,044 6 payments
  7. R&D UPPER EXT $24,000 23 payments
  8. INSIGNIA $20,000 2 payments
  9. TRIDENT $15,000 1 payment
  10. ACCOLADE $15,000 1 payment
  11. Other $76,426 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Wright Medical Technology, Inc. $2,734 7 payments
  2. Stryker Corporation $2,319 1 payment

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$208,126

Of which drugs: $44

Medicare patients

375

Average age 73

Services billed

1,257

191 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 28%
Diabetes 25%
Depression 23%
Chronic kidney disease 19%
Osteoporosis 19%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 28 57 $44

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

241 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record